In today’s rapidly evolving biotech landscape, the rules of biologic development are being rewritten. Therapeutic targets are becoming more complex, modalities more sophisticated, and the margin for clinical success narrower than ever. Against this backdrop, companies are being challenged not just to innovate—but to fundamentally rethink how innovation happens.
For Ilse Roodink, CSO of AVS Bio Netherlands, that rethink began with a simple but powerful premise: what if the bottlenecks in antibody discovery weren’t inevitable?
Founded in 2023 as a carve-out from Charles River, AVS Bio was built on more than three decades of scientific groundwork. At the heart of the company lies a unique platform which harnesses the power of the immune-naïve background of the company’s specific pathogen-free egg technology—an approach that has quietly supported biologics development in both animal and human health for years.
But AVS Bio is not just a continuation of that legacy—it is an evolution of it. In 2025, the company expanded its biologics development platform with industry-leading antibody discovery and optimization, and protein production expertise and technologies, strengthening AVS Bio’s position at the forefront of supporting biologics developers in their journey from early discovery through preclinical development with sophisticated solutions.
From Bottlenecks to Breakthroughs
Biologic development has long been constrained by a critical challenge: the ability to efficiently discover and optimize high-quality antibodies against increasingly difficult targets. As disease biology becomes more nuanced, traditional approaches often fall short—too slow, too rigid, or too narrow in scope.
AVS Bio was designed to confront this challenge head-on.
By integrating in vivo, in vitro, and in silico technologies into a single, cohesive platform, the company has created a system that doesn’t just accelerate discovery—it reshapes it. Instead of fragmented workflows and disconnected tools, AVS Bio offers a unified approach that enables scientists to move seamlessly from early discovery to preclinical development.
The result is not just speed, but precision: the ability to generate and refine antibody candidates that are truly fit for purpose, meeting predefined functional criteria and developability profiles.
Customization as a Competitive Edge
In an industry crowded with capable players, differentiation often comes down to flexibility. And this is where AVS Bio has made a deliberate—and strategic—choice.
Rather than standardizing its offerings, the company leans into customization. Each program is designed in close collaboration with partners, aligning scientific strategy with specific therapeutic goals. This high-touch, tailored approach allows AVS Bio to do something many platforms struggle with: consistently deliver candidates that meet the exact requirements for clinical success.
It’s not just about providing services—it’s about co-creating solutions.
Meeting the Moment of Complexity
The timing of AVS Bio’s emergence is no coincidence. The biotech industry is entering a new phase—one defined by complexity.
Multi-specific antibodies, novel modalities, and increasingly intricate targets are no longer the exception; they are the expectation. These advances promise better therapies, but they also demand more sophisticated discovery platforms—systems capable of generating diverse, adaptable outputs that can keep pace with scientific ambition.
AVS Bio’s response is rooted in diversity.
By prioritizing the generation of broad, high-quality antibody repertoires early in the discovery process, the company enables more effective narrowing and optimization downstream. In a world where the “right” candidate is harder to find, starting with a richer pool of possibilities is not just advantageous—it’s essential.
Building for What Comes Next
Looking ahead, AVS Bio is not standing still. The company is actively expanding its platform—investing in advanced screening technologies, deepening its computational capabilities, and enhancing production processes to support the next generation of biologics.
These efforts are not just about growth; they are about readiness. Readiness for a future where therapeutic innovation will demand even greater integration between biology, data, and engineering.
Defining Success Beyond Technology
For Ilse, success is not defined solely by technological achievement. It is measured by impact.
It is seen in strong, enduring partnerships.
In therapeutic candidates that advance into clinical evaluation and generation of superior products that support the development of biologics.
In a reputation built on trust, rigor, and the consistent delivery of high-quality antibodies—even against the most challenging targets.
And perhaps most importantly, it is reflected in the people behind the platform—the scientists whose expertise and curiosity continue to push the boundaries of what is possible.
A New Paradigm for Discovery
As biologics move into an era of unprecedented complexity, the companies that will lead are those willing to rethink not just what they build, but how they build it.
AVS Bio represents one such rethink: a shift toward integration over fragmentation, customization over standardization, and diversity over limitation.
In doing so, it is not just participating in the future of antibody discovery—it is helping to define it.